secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273278
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q3 net loss $53.9M; obesity drug WVE-007 shows 85% Activin E reduction
--------------------------------------------------------------------------------

- WVE-007: dose-dependent Activin E reduction up to 85% in INLIGHT; sustained through 6 months at lowest dose; supports once/twice yearly dosing.
- WVE-006 recapitulated MZ phenotype: AAT >20 µM during acute phase, wild-type M-AAT 64% of serum AAT, Z-AAT reduced 60% in RestorAATion-2.
- Cash $196.2M at Sept 30; $72.1M post-quarter from ATM and GSK milestones extend runway into Q2 2027.
- Net loss $53.9M vs $61.8M prior year; revenue $7.6M vs ($7.7M); R&D $45.9M, G&A $18.1M.
- Milestones: INLIGHT body weight data Q4 2025; NDA for WVE-N531 in 2026; IND for WVE-003 Phase 2/3 H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525273278/0001193125-25-273278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525273278/d44041d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer